PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsPersonalised medicine patents disputed at US Supreme Court

BioNews

Personalised medicine patents disputed at US Supreme Court

Published 9 December 2011 posted in News and appears in BioNews 638

Author

Nishat Hyder

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A patent for a diagnostic test is currently under consideration by the US Supreme Court. The eventual decision may have profound implications for the burgeoning 'personalised medicine' industry which often relies on DNA tests to guide physicians in choosing tailored therapies for patients...

A patent for a diagnostic test is currently under consideration by the US Supreme Court. The eventual decision may have profound implications for the burgeoning personalised medicine industry which often relies on DNA tests to guide physicians in choosing tailored therapies for patients.

In the current case, the Mayo Clinic, based in Minnesota, is challenging a patent held by Swiss-based, Nestlé-owned Prometheus Laboratories in an intellectual property spat that has been going on for seven years. The test under consideration helps doctors determine the optimum individual dosage of the drug thiopurine, used to treat autoimmune illnesses, such as Crohn's disease and lupus. After the patient has been given thiopurine, a blood sample is taken to measure the number of metabolites, and the results compared against predetermined ranges — the doctor can then decide whether to alter the dose of the drug.

The Mayo Clinic previously used Prometheus' test but developed their own allegedly more accurate test in 2004 and Prometheus Laboratories sued the Mayo Clinic for breaching their patent protection. However, a federal court judge ruled that the original Prometheus patent was invalid, on grounds that it was based on a natural phenomenon and mental processes, neither of which is patentable. The decision was overturned by the US Court of Appeals, leading the Mayo Clinic to the present appeal to the Supreme Court.

The legal issue is, in the words of Justice Stephen Breyer of the Supreme Court: 'What has to be added to a law of nature to make it a patentable process?' And by extension, has Prometheus Laboratories successfully done that?

Fellow Supreme Court Justice Elena Kagan thinks not: 'This is not a treatment protocol, it's not a treatment regimen… All you have done is pointed out a set of facts that exist in the world [...] and are claiming protection for something that anybody can try to make use of in any way, and you are saying, "You have to pay us"'.

Representing Prometheus Laboratories, Mr Richard Bress, said: 'The idea that we are not novel because people took some of the same steps along the way to invention that we actually succeeded in is wrong'. Furthermore, argued Bress, 'the court has never suggested that there is an extra-statutory limitation that prevents patents on developing useful information, even if they have a mental step at the end'.

The Obama administration openly supports Mayo Clinic's position. Solicitor General Donald Verrilli stated: 'You can't get a patent by tacking a mental step onto an utterly conventional process for administering drugs and testing their effects'.

This case is about more than the determining the boundaries of the legal test for a medical patent, and ascertaining whether those conditions have been met by Prometheus. There are broader concerns around the impact on innovation in personalised medicine and the possible creation of market and knowledge monopolies. Mr Stephen Shapiro, representing Mayo Clinic, argued that Prometheus' patent was so wide as to prevent a patient seeking a 'second opinion…[using] a better metabolite test with more accurate numbers' from the Mayo Clinic.

The case was heard by a full Supreme Court, who will deliver their ruling next year.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
17 May 2013 • 2 minutes read

Lung cancer gene test approved as 'companion diagnostic'

by Dr Jamie Heather

The US medicines regulator, the Food and Drug Administration, has approved a genetic test to help doctors select suitable lung cancer patients to be treated with the drug erlotinib...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 March 2013 • 3 minutes read

Myriad Genetics: landmark ruling for gene patenting

by Dr Sarah West

In the latest instalment of a highly contested case, the US Federal Circuit Court of Appeals in Washington DC upheld Myriad Genetics' right to patent two genes, BRCA1 and BRCA2,which are associated with the risk of breast and ovarian cancer....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 March 2013 • 2 minutes read

Personal genomics company 23andMe awarded Parkinson's gene patent

by Ruth Saunders

23andMe, a personal genomics company, announced last week that it had been successfully awarded a patent for a gene variant which appears to protect against a high-risk mutation for Parkinson's disease...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
28 January 2013 • 2 minutes read

Myriad Genetics acquires patent on another breast cancer-linked gene

by Ayesha Ahmad

Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 January 2013 • 2 minutes read

Successful trial of genetic test to guide personalised cancer therapy

by Dr Louisa Petchey

A new genetic test that will help to tailor drugs to cancer patients' individual tumours has been successfully trialled in the US...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 January 2013 • 2 minutes read

UK Supreme Court upholds gene patent

by Martin Turner

In what appears to be the end of a long running legal saga, a ruling by the UK's Supreme Court has found in favour of a patent for a gene and the protein sequence it encodes. Lawyers say that the ruling will make it easier to patent discoveries which do not have a clear demonstrated application, a result that will largely please the private bioscience industry but may alarm many who believe that human genes should not be patentable....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 November 2012 • 2 minutes read

NHS may be infringing on DNA patents

by Nishat Hyder

The NHS may be at risk of being sued over patent infringement, says a new report published by the Human Genetics Commission (HGC), the UK Government's genetics advisory body...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 April 2010 • 2 minutes read

Gene patents may be damaging the genetic testing market, study claims

by Harriet Vickers

Researchers examining gene patents used in diagnostic tests say these can block competition and slow innovation, rather than spur development of new technologies for assessing the risk of genetic diseases...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Evidence found that Asian populations interbred with ancient ancestors

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856